Organon & Co. (OGN)
NYSE: OGN · Real-Time Price · USD
10.45
+0.09 (0.87%)
Sep 17, 2025, 4:00 PM EDT - Market closed
Organon & Co. Revenue
Organon & Co. had revenue of $1.59B in the quarter ending June 30, 2025, a decrease of -0.81%. This brings the company's revenue in the last twelve months to $6.28B, down -1.02% year-over-year. In the year 2024, Organon & Co. had annual revenue of $6.40B with 2.24% growth.
Revenue (ttm)
$6.28B
Revenue Growth
-1.02%
P/S Ratio
0.43
Revenue / Employee
$628,100
Employees
10,000
Market Cap
2.72B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 6.40B | 140.00M | 2.24% |
| Dec 31, 2023 | 6.26B | 89.00M | 1.44% |
| Dec 31, 2022 | 6.17B | -130.00M | -2.06% |
| Dec 31, 2021 | 6.30B | -228.00M | -3.49% |
| Dec 31, 2020 | 6.53B | -1.25B | -16.01% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 422.82B |
| Johnson & Johnson | 90.63B |
| Merck & Co. | 63.62B |
| AbbVie | 58.33B |
| AstraZeneca | 56.50B |
| Novartis AG | 55.19B |
| Eli Lilly and Company | 53.26B |
| Novo Nordisk | 49.11B |
OGN News
- 16 days ago - US Food and Drug Administration (FDA) Approves Henlius and Organon's BILDYOS® (denosumab-nxxp) and BILPREVDA® (denosumab-nxxp), Biosimilars to PROLIA (denosumab) and XGEVA (denosumab), Respectively - Business Wire
- 5 weeks ago - Organon: Valuation Discount Offset By Structural Headwinds - Seeking Alpha
- 6 weeks ago - Organon Q2 Earnings: It May Be Time To Desert This Sinking Ship (Downgrade) - Seeking Alpha
- 6 weeks ago - Organon & Co. (OGN) Q2 2025 Earnings Call Transcript - Seeking Alpha
- 6 weeks ago - Organon Reports Results for the Second Quarter Ended June 30, 2025 - Business Wire
- 2 months ago - Organon To Report Second Quarter 2025 Results and Host Conference Call on August 5, 2025 - Business Wire
- 2 months ago - OGN Shareholders Have the Right to Lead the Organon & Co. Securities Lawsuit - Contact the DJS Law Group to Discuss Your Rights - OGN - PRNewsWire
- 2 months ago - INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Organon - GlobeNewsWire